Phase I Study to Evaluate the Tolerability, Pharmacokinetics, Immunogenicity, Safety of Dose Escalation and Preliminary Efficacy of GR1401 in Patients with Advanced Solid Tumors
Latest Information Update: 08 Jan 2018
At a glance
- Drugs GR 1401 (Primary)
- Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Genrix (Shanghai) Biopharmaceuticals
- 08 Jan 2018 New trial record